Ascendis Pharma A/S - Ordinary Share (ASND) closed at $267.07 on November 12, 2026, up 3.0% from the previous close, on volume of 1,151,681 shares (30-day average 679,075).
Data as of November 12, 2026.
12-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | 16-Oct-26 240 P : 18-Dec-26 240 C : 18-Dec-26 240 P | 600 | |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Ascendis Pharma Grants 28,030 Employee Warrants
TipRanks (Thu, 12-Nov 4:38 PM ET)
Ascendis Pharma Files Unaudited September 2026 Financial Statements
TipRanks (Thu, 12-Nov 8:57 AM ET)
Ascendis Pharma Reports Q3 2026 Results and Positive CHMP, COMP Opinions for TransCon CNP
TipRanks (Thu, 12-Nov 8:57 AM ET)
Ascendis Pharma A/S Non-GAAP EPS of €1.71, revenue of €369.6M
Seeking Alpha News (Thu, 12-Nov 7:41 AM ET)
Ascendis Pharma Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 12-Nov 7:30 AM ET)
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
Globe Newswire (Tue, 10-Nov 4:01 PM ET)
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), Harrow Health (HROW)
TipRanks (Tue, 10-Nov 10:40 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Ascendis Pharma (ASND)
TipRanks (Mon, 9-Nov 8:50 AM ET)
Analysts Offer Insights on Healthcare Companies: Envoy Medical (COCH) and Ascendis Pharma (ASND)
TipRanks (Mon, 9-Nov 7:40 AM ET)
Globe Newswire (Fri, 6-Nov 8:00 AM ET)
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Ascendis Pharma A/S - Ordinary Share trades on the NASDAQ stock market under the symbol ASND.
As of November 12, 2026, ASND stock price climbed to $267.07 with 1,151,681 million shares trading.
ASND has a beta of 0.33, meaning it tends to be less sensitive to market movements. ASND has a correlation of 0.01 to the broad based SPY ETF.
ASND has a market cap of $17.57 billion. This is considered a Large Cap stock.
Last quarter Ascendis Pharma A/S - Ordinary Share reported $394 million in Revenue and $1.05 earnings per share. This beat revenue expectation by $41 million and exceeded earnings estimates by $.27.
In the last 3 years, ASND traded as high as $282.15 and as low as $86.55.
The top ETF exchange traded funds that ASND belongs to (by Net Assets): TCAF, IBB, IWP, IWR, IWF.
ASND has outperformed the market in the last year with a price return of +32.8% while the SPY ETF gained +12.0%. ASND has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.9% and +7.0%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
ASND support price is $255.21 and resistance is $263.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASND shares will trade within this expected range on the day.